Zacks Investment Research upgraded shares of NewLink Genetics (NASDAQ:NLNK) from a hold rating to a buy rating in a report published on Wednesday. Zacks Investment Research currently has $9.00 target price on the biotechnology company’s stock.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

NLNK has been the topic of a number of other research reports. Cantor Fitzgerald reissued a buy rating and issued a $26.00 price target on shares of NewLink Genetics in a research note on Monday, September 25th. ValuEngine raised NewLink Genetics from a strong sell rating to a sell rating in a research note on Thursday, September 7th. Stifel Nicolaus lifted their price target on NewLink Genetics from $14.00 to $29.00 and gave the stock a buy rating in a research note on Monday, September 11th. Jefferies Group raised NewLink Genetics from a hold rating to a buy rating and lifted their price target for the stock from $7.00 to $26.00 in a research note on Friday, September 8th. Finally, Bank of America assumed coverage on NewLink Genetics in a research note on Friday, October 13th. They issued a buy rating and a $22.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $23.29.

Shares of NewLink Genetics (NASDAQ NLNK) traded down $1.06 on Wednesday, reaching $9.00. The company had a trading volume of 1,850,000 shares, compared to its average volume of 822,363. The stock has a market cap of $326.00, a PE ratio of -3.69 and a beta of 1.10. NewLink Genetics has a 1 year low of $5.90 and a 1 year high of $25.17.

A number of hedge funds and other institutional investors have recently made changes to their positions in NLNK. Perceptive Advisors LLC acquired a new stake in NewLink Genetics during the 3rd quarter worth about $4,581,000. Candriam Luxembourg S.C.A. boosted its position in NewLink Genetics by 337.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock worth $3,339,000 after acquiring an additional 253,000 shares during the period. Ameriprise Financial Inc. boosted its position in NewLink Genetics by 207.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock worth $3,176,000 after acquiring an additional 210,360 shares during the period. Point72 Asset Management L.P. acquired a new stake in NewLink Genetics during the 3rd quarter worth about $1,819,000. Finally, GSA Capital Partners LLP boosted its position in NewLink Genetics by 653.7% during the 3rd quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock worth $1,345,000 after acquiring an additional 114,620 shares during the period. Hedge funds and other institutional investors own 52.63% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/newlink-genetics-nlnk-upgraded-at-zacks-investment-research/1798148.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with Analyst Ratings Network's FREE daily email newsletter.